Seaport Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to advancing a pipeline of transformative medicines for neuropsychiatric disorders. The company utilizes its proprietary Glyph platform, a specialized drug-delivery technology designed to leverage the body’s natural lymphatic transport system. This approach allows for the oral administration of therapeutics that would otherwise be limited by poor absorption or significant first-pass metabolism in the liver, potentially reducing side effects and enhancing therapeutic reach to the brain. Seaport’s clinical pipeline is focused on addressing significant unmet needs in mental health. Its lead candidates include SPT-300, an oral prodrug of allopregnanolone being developed for the treatment of major depressive disorder (MDD) with postpartum depression; SPT-320, an oral prodrug of agomelatine intended for generalized anxiety disorder (GAD); and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen being developed for various neuropsychiatric conditions. Founded by PureTech Health and led by an experienced management team with a track record in CNS drug development, Seaport Therapeutics aims to redefine the treatment landscape for depression, anxiety, and other neurological conditions by optimizing the pharmacological profiles of proven molecules through innovative lymphatic targeting.
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
...and much more!